Clinical Trial Update: A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis [Phase 2]

View source ↗

Summary

Phase 2 trial update for RC18 antibody fusion protein targeting systemic myasthenia gravis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Myasthenia Gravis

Drugs mentioned

• RC18 (TACI-CAML interactor antibody fusion protein) (RC18)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Systemic Myasthenia Gravis | Phase 2 | Status: COMPLETED